DE3008632C2 - - Google Patents

Info

Publication number
DE3008632C2
DE3008632C2 DE3008632A DE3008632A DE3008632C2 DE 3008632 C2 DE3008632 C2 DE 3008632C2 DE 3008632 A DE3008632 A DE 3008632A DE 3008632 A DE3008632 A DE 3008632A DE 3008632 C2 DE3008632 C2 DE 3008632C2
Authority
DE
Germany
Prior art keywords
indole
imidazolylmethyl
lower alkyl
solution
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE3008632A
Other languages
German (de)
English (en)
Other versions
DE3008632A1 (de
Inventor
Peter Edward Dr. Canterbury Kent Gb Cross
Roger Peter Dr. Dover Kent Gb Dickinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp SRL filed Critical Pfizer Corp SRL
Publication of DE3008632A1 publication Critical patent/DE3008632A1/de
Application granted granted Critical
Publication of DE3008632C2 publication Critical patent/DE3008632C2/de
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE19803008632 1979-03-07 1980-03-06 Indol-derivate, verfahren zu ihrer herstellung und ihre verwendung Granted DE3008632A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB7908123 1979-03-07

Publications (2)

Publication Number Publication Date
DE3008632A1 DE3008632A1 (de) 1980-10-16
DE3008632C2 true DE3008632C2 (enExample) 1988-02-25

Family

ID=10503707

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19803008632 Granted DE3008632A1 (de) 1979-03-07 1980-03-06 Indol-derivate, verfahren zu ihrer herstellung und ihre verwendung

Country Status (36)

Country Link
US (1) US4273782A (enExample)
JP (1) JPS55133380A (enExample)
KR (1) KR850000760B1 (enExample)
AR (1) AR227015A1 (enExample)
AT (1) AT375366B (enExample)
AU (1) AU516957B2 (enExample)
BE (1) BE882113A (enExample)
CA (1) CA1120479A (enExample)
CH (1) CH649546A5 (enExample)
CS (1) CS253702B2 (enExample)
DD (1) DD149525A5 (enExample)
DE (1) DE3008632A1 (enExample)
DK (1) DK151884C (enExample)
ES (2) ES489220A0 (enExample)
FI (1) FI66860C (enExample)
FR (1) FR2450832A1 (enExample)
GR (1) GR67237B (enExample)
HK (1) HK89884A (enExample)
HU (1) HU184727B (enExample)
IE (1) IE49542B1 (enExample)
IL (1) IL59524A (enExample)
IT (1) IT1218420B (enExample)
KE (1) KE3467A (enExample)
LU (1) LU82224A1 (enExample)
MY (1) MY8500285A (enExample)
NL (1) NL182959C (enExample)
NO (1) NO152217C (enExample)
NZ (1) NZ193052A (enExample)
PH (1) PH15198A (enExample)
PL (1) PL128296B1 (enExample)
PT (1) PT70914A (enExample)
SE (1) SE440778B (enExample)
SG (1) SG67284G (enExample)
SU (1) SU1277894A3 (enExample)
YU (1) YU41911B (enExample)
ZA (1) ZA801328B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4414159A (en) * 1980-09-26 1983-11-08 E. I. Du Pont De Nemours & Co. Vinyl ether monomers and polymers therefrom
US4444775A (en) * 1981-06-22 1984-04-24 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridines
KR840000529A (ko) * 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
ZA825413B (en) * 1981-08-26 1983-06-29 Pfizer Thromboxane synthetase inhibitors, processes for their production, and pharmaceutical compositions comprising them
US4460777A (en) * 1981-11-19 1984-07-17 Ciba-Geigy Corporation N-Substituted-2-pyridylindoles
US4478842A (en) * 1981-11-19 1984-10-23 Ciba-Geigy Corporation N-Substituted-2-pyridylindoles
US4539410A (en) * 1982-09-30 1985-09-03 Ciba-Geigy Corporation N-Substituted-2-(1-imidazolyl)indoles
US4436746A (en) 1982-09-30 1984-03-13 Ciba-Geigy Corporation Thromboxane synthetase inhibitory N-substituted-2-(1-imidazolyl)indoles
AT376436B (de) * 1982-11-05 1984-11-26 Laevosan Gmbh & Co Kg Verfahren zur herstellung neuer thiophen-2carbons[urederivate und pharmazeutisch vertraeglicher saeure- oder basenadditionssalze davon
US4511573A (en) * 1983-05-17 1985-04-16 Ciba-Geigy Corporation 3-Substituted-2-(heteroaryl) indoles
ATE90076T1 (de) 1986-03-27 1993-06-15 Merck Frosst Canada Inc Tetrahydrocarbazole ester.
JPH0832679B2 (ja) * 1986-09-05 1996-03-29 理化学研究所 Ｎ―フタルイシド誘導体及びその製造法
GR871809B (en) * 1986-11-28 1988-03-07 Glaxo Group Ltd Process for the preparation of tricyclic ketones
EP0427860A1 (en) * 1989-03-31 1991-05-22 Kyoto Pharmaceutical Industries, Ltd. New imidazole derivatives, production thereof, and uses thereof as medicines
CZ288351B6 (en) * 1990-06-07 2001-05-16 Astrazeneca Ab Nitrogenous heterocyclic compound, process of its preparation and use as well as a medicament containing thereof
DE4023215A1 (de) * 1990-07-21 1992-01-23 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, sie enthaltende mittel und deren verwendung
JPH06500551A (ja) * 1990-09-13 1994-01-20 ビーチャム・グループ・パブリック・リミテッド・カンパニー ５ｈｔ受容体アンタゴニストとしてのインドールウレア
US5162337A (en) * 1990-10-05 1992-11-10 Merck & Co., Inc. Animal growth promotion
US5120749A (en) * 1991-02-20 1992-06-09 Abbott Laboratories Platelet activating antagonists
DE69212844T2 (de) * 1991-12-18 1997-01-09 Schering Corp., Kenilworth, N.J. Imidazolyl oder imidazolylalkyl substituiert mit einem 4- oder 5-gliedrigen stickstoff enthaltenden heterozyklischen ring
EP0597112A4 (en) * 1992-03-27 1994-06-22 Kyoto Pharma Ind Novel imidazole derivative, pharmaceutical use thereof, and intermediate therefor.
US5538973A (en) * 1992-03-27 1996-07-23 Kyoto Pharmaceutical Industries, Ltd. Imidazole derivative, pharmaceutical use thereof, and intermediate therefor
JPH0632913U (ja) * 1992-09-18 1994-04-28 三洋電機株式会社 床暖房用パネル
AP2000001929A0 (en) * 1998-03-31 2000-09-30 Inst For Pharm Discovery Inc Substituted indolealkanoic acids.
WO2004024726A1 (en) * 2002-09-12 2004-03-25 F. Hoffmann-La Roche Ag N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes
DE60323130D1 (de) * 2002-11-25 2008-10-02 Hoffmann La Roche Indolderivaten
EP1569899B1 (en) * 2002-12-10 2006-06-28 Wyeth Substituted 3-alkyl- and 3-arylalkyl-1h-indol-1-yl-acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
MXPA06012683A (es) * 2004-05-03 2007-01-16 Hoffmann La Roche Derivados de indolilo como moduladores de receptor x del higado.
MX2007004525A (es) * 2004-10-12 2007-09-19 Decode Genetics Inc Sulfonamidas biciclicas peri-sustituidas para enfermedad de arteria oclusiva.
RU2008110908A (ru) * 2005-08-25 2009-09-27 Шеринг Корпорейшн (US) Производные имидазола в качестве функционально селективных агонистов альфа2с адренорецепторов
US8399666B2 (en) * 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
CA2652152A1 (en) * 2006-05-16 2007-11-29 Decode Genetics Ehf Process for preparing 7-(acryloyl)indoles
ES2391671T3 (es) 2006-07-22 2012-11-28 Oxagen Limited Compuestos con actividad antagonista de CRTH2
TW200920369A (en) * 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
EP2234608A2 (en) 2007-12-11 2010-10-06 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
DK2250161T3 (da) 2008-01-18 2014-01-27 Atopix Therapeutics Ltd Forbindelser med CRTH2-antagonistaktivitet
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
EP2240444A1 (en) * 2008-01-22 2010-10-20 Oxagen Limited Compounds having crth2 antagonist activity
WO2009093026A1 (en) * 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
JP5791500B2 (ja) * 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
EP2739144A4 (en) * 2011-06-20 2015-04-01 Alzheimer S Inst Of America Inc COMPOUNDS AND ITS THERAPEUTIC USE
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
WO2019191410A1 (en) * 2018-03-29 2019-10-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibitors for the β-catenin / t-cell factor protein–protein interaction

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL125443C (enExample) * 1963-06-06
US3370063A (en) * 1964-10-05 1968-02-20 Mcneilab Inc Substituted dimethoxy indoles and method of making the same
US3621027A (en) * 1968-03-18 1971-11-16 Endo Lab 1-aminoalkyl-2,6-diaryl 4,5,6,7 tetrahydro-4-oxindales
US3931229A (en) * 1973-08-23 1976-01-06 Warner-Lambert Company 3-Thiomethyl-2[2-(dialkylamino)ethyl]indoles
US4059583A (en) * 1975-11-13 1977-11-22 Mcneil Laboratories, Incorporated Substituted indoles
AU523536B2 (en) * 1977-08-26 1982-08-05 Wellcome Foundation Limited, The Imidazoles and methods of preparing them
US4140858A (en) * 1977-12-19 1979-02-20 Warner-Lambert Company 3-(1H-imidazol-1-ylmethyl)-2-(disubstitutedaminomethyl)indoles and a method for their production
EP0003901B1 (en) * 1978-02-24 1981-08-05 Pfizer Limited 3-(imidazol-1-ylalkyl)indoles as selective inhibitors of thromboxane synthetase,pharmaceutical compositions thereof, and methods for preparing them

Also Published As

Publication number Publication date
SE8001736L (sv) 1980-09-08
ES8104278A1 (es) 1981-04-01
IT1218420B (it) 1990-04-19
NO800650L (no) 1980-09-08
NL182959C (nl) 1988-06-16
NO152217C (no) 1985-08-21
NZ193052A (en) 1984-07-06
AT375366B (de) 1984-07-25
BE882113A (fr) 1980-09-08
SU1277894A3 (ru) 1986-12-15
AU516957B2 (en) 1981-07-02
IL59524A0 (en) 1980-06-30
HU184727B (en) 1984-10-29
PL222470A1 (enExample) 1980-12-01
KR830001928A (ko) 1983-05-19
SG67284G (en) 1985-03-15
ZA801328B (en) 1981-03-25
YU61480A (en) 1983-12-31
SE440778B (sv) 1985-08-19
IL59524A (en) 1982-11-30
FR2450832A1 (fr) 1980-10-03
NL8001351A (nl) 1980-09-09
ES8205789A1 (es) 1982-08-01
PT70914A (en) 1980-04-01
LU82224A1 (fr) 1980-06-06
DK151884C (da) 1988-06-13
ES496889A0 (es) 1982-08-01
DK151884B (da) 1988-01-11
DK42580A (da) 1980-09-08
GR67237B (enExample) 1981-06-25
DD149525A5 (de) 1981-07-15
KR850000760B1 (ko) 1985-05-25
FI800672A7 (fi) 1980-09-08
KE3467A (en) 1984-11-09
CS253702B2 (en) 1987-12-17
ES489220A0 (es) 1981-04-01
JPS55133380A (en) 1980-10-17
MY8500285A (en) 1985-12-31
IT8020399A0 (it) 1980-03-06
JPS6141513B2 (enExample) 1986-09-16
PH15198A (en) 1982-09-17
HK89884A (en) 1984-11-23
PL128296B1 (en) 1984-01-31
AR227015A1 (es) 1982-09-15
FR2450832B1 (enExample) 1983-04-22
FI66860C (fi) 1984-12-10
ATA125780A (de) 1983-12-15
DE3008632A1 (de) 1980-10-16
AU5623180A (en) 1980-09-11
US4273782A (en) 1981-06-16
CA1120479A (en) 1982-03-23
CH649546A5 (de) 1985-05-31
IE49542B1 (en) 1985-10-30
IE800453L (en) 1980-09-07
FI66860B (fi) 1984-08-31
NO152217B (no) 1985-05-13
YU41911B (en) 1988-02-29

Similar Documents

Publication Publication Date Title
CH649546A5 (de) Indol-derivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel.
DE3001762A1 (de) Imidazol-derivate, verfahren zu ihrer herstellung und solche derivate enthaltende arzneimittel
DE69132340T2 (de) Kondensiertes pyrazinderivat
DE1957706C3 (de) Kernsubstituierte 3-Phenoxy-l-phenoxyalkylamino-propan-2-ole und Arzneimittel auf deren Basis
DE69708142T2 (de) 1-phenylpyrozol-verbindungen und ihre medizinische anwendung
DE69525479T2 (de) 4-[(heterocycloalkyl-oder heteroaromatische)-substituiertes phenyl]-2-azetidinone zur verwendung als hypolipidemische agentien.
DE602004011230T2 (de) Nitrooxyderivate von losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan als angiotensin-ii-rezeptor-blocker zur behandlung von herz-kreislauf-erkrankungen
DD147943A5 (de) Verfahren zur herstellung von alkyl-imidazol-derivaten
DE69014351T2 (de) Pyridincarbonsäureamid-Derivate und diese enthaltende pharmazeutische Zusammensetzungen.
DD202290A5 (de) Verfahren zur herstellung von indolderivaten
DD215546A5 (de) Verfahren zur herstellung bicyclischer thromboxansynthetase-inhibitoren
DE2559509A1 (de) Benzcyloamidderivate und verfahren zu ihrer herstellung sowie pharmazeutische mittel, worin sie enthalten sind
DE68904586T2 (de) Histamin-derivat, verfahren zu dessen herstellung und therapeutischen anwendung.
DD201891A5 (de) Verfahren zur herstellung von aza-biozyklo-oktan-karboxylsaeuren
DE68903531T2 (de) Substituierte 1-(1h-imidazol-4-yl)alkyl-benzamide.
DD202714A5 (de) Verfahren zur herstellung 3-substituierter indolylacrylsaeurederivate
DD201903A5 (de) Verfahren zur herstellung von derivaten des thienopyridonons
DE68911699T2 (de) Diamin-Verbindungen.
DE2112349A1 (de) Di- und tri-substituierte Imidazole
DE3788507T2 (de) Substituierte 1H-Imidazole.
DE2932967A1 (de) Imidazol-derivate, verfahren zu ihrer herstellung und solche derivate enthaltende arzneimittel
EP0410358B1 (de) Aromatische Carbonsäureamide, ihre Herstellung und Verwendung für Heilmittel
DE4320801A1 (de) 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel
EP0014847A1 (de) Pyrazolderivate, diese enthaltende pharmazeutische Zubereitungen und Verfahren zu ihrer Herstellung
EP0283857B1 (de) Benzylidenamino-, benzylamino- und benzoylamino-imidazolderivate

Legal Events

Date Code Title Description
OAM Search report available
OC Search report available
OD Request for examination
8128 New person/name/address of the agent

Representative=s name: LEDERER, F., DIPL.-CHEM. DR., PAT.-ANW., 8000 MUEN

D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee